Search Results

You are looking at 201 - 210 of 534 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Jonathan R. Strosberg, Gary D. Hammer, and Gerard M. Doherty

Edited by Kerrin G. Robinson

revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors . Am J Surg Pathol 2002 ; 26 : 1612 – 1619 . 34 DeLellis RA Lloyd RV Heitz PU Eng C , eds. World Health Organization Classification of Tumours: Pathology

Full access

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino

pathology assessments to establish cTNM and ypTNM stages has never been validated and may not be appropriate. Therefore, new cTNM and ypTNM stage groupings and prognostic information were added to the eighth edition to overcome these issues. New clinical

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

. Pathology revealed omentum with acute inflammation and abscess formation, with no evidence of malignancy in 13 lymph nodes. He recovered from surgery and was discontinued from the trial, but continued on single-agent dabrafenib due to the BRAF V600E

Full access

Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes

pathology report noted features of ganglioglioma with mixed neuronal and glial growth patterns. In regions of the tumor with an abundant glial component, there was evidence of moderate cell proliferation as assessed by Ki-67 (MIB-1) immunohistochemistry (A

Full access

Mariam Naveed, Meredith Clary, Chul Ahn, Nisa Kubiliun, Deepak Agrawal, Byron Cryer, Caitlin Murphy, and Amit G. Singal

, gastrointestinal symptoms), laboratory data (eg, iron deficiency anemia), radiologic data (eg, bowel thickening on imaging), and prior pathology and colonoscopy data (eg, history of adenomas). Family history of colon cancer denoting high-risk screening was defined

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet 1997 ; 6 : 1383 – 1387 . 3 Starink TM Hausman R . The cutaneous pathology of extrafacial lesions in Cowden's disease . J Cutan Pathol 1984 ; 11 : 338

Full access

M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz

her tumor 3 weeks after discontinuing imatinib. Because of the location of the tumor and involvement of the SMV, a Whipple procedure was required. However, it was believed that the neoadjuvant imatinib made this procedure possible. Pathology revealed a

Full access

Lara Franziska Stolzenbach, Giuseppe Rosiello, Angela Pecoraro, Carlotta Palumbo, Stefano Luzzago, Marina Deuker, Zhe Tian, Anne-Sophie Knipper, Raisa Pompe, Kevin C. Zorn, Shahrokh F. Shariat, Felix K.H. Chun, Markus Graefen, Fred Saad, and Pierre I. Karakiewicz

final pathology at RP; the rates of upstaging, defined as a non–organ-confined tumor (stage pT3+/pN1) at RP; and the rates of upgrading and/or upstaging, defined as a combination of both, were tabulated for Black and White patients. Specifically, 3

Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

about the reliability of biomarker testing in breast cancer. ASCO, the College of American Pathology, and NCCN issued technology assessments on methods to assure high-quality performance and interpretation of ER, PR, and HER2 testing. 3 - 6